HC Wainwright Lowers RAPT Therapeutics (NASDAQ:RAPT) Price Target to $43.00

RAPT Therapeutics (NASDAQ:RAPT – Get Rating) had its price target reduced by HC Wainwright from $50.00 to $43.00 in a report issued on Wednesday, The Fly reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for RAPT Therapeutics’ Q1 2023 earnings at ($0.76) EPS, Q2 2023 earnings at ($0.80) EPS, Q3 2023 earnings at ($0.85) EPS, Q4 2023 earnings at ($0.87) EPS, FY2023 earnings at ($3.27) EPS and FY2024 earnings at ($3.86) EPS.

Several other research analysts have also issued reports on the company. Piper Sandler dropped their target price on RAPT Therapeutics from $34.00 to $33.00 in a research report on Thursday, December 8th. Wells Fargo & Company dropped their target price on RAPT Therapeutics from $55.00 to $48.00 and set an overweight rating for the company in a research report on Wednesday, January 4th. The Goldman Sachs Group initiated coverage on shares of RAPT Therapeutics in a research note on Thursday, December 1st. They set a buy rating and a $27.00 price target for the company. Finally, Guggenheim initiated coverage on shares of RAPT Therapeutics in a research note on Wednesday, January 4th. They set a buy rating and a $55.00 price target for the company. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of Buy and a consensus target price of $41.38.

RAPT Therapeutics Price Performance

Shares of NASDAQ:RAPT opened at $18.94 on Wednesday. RAPT Therapeutics has a 1 year low of $9.85 and a 1 year high of $32.45. The business has a 50 day simple moving average of $27.10 and a two-hundred day simple moving average of $23.28. The firm has a market capitalization of $649.45 million, a PE ratio of -7.34 and a beta of 0.46.

Insider Buying and Selling

In other RAPT Therapeutics news, Director Wendye Robbins acquired 2,500 shares of RAPT Therapeutics stock in a transaction that occurred on Tuesday, March 14th. The stock was bought at an average price of $18.99 per share, with a total value of $47,475.00. Following the completion of the purchase, the director now directly owns 14,900 shares of the company’s stock, valued at approximately $282,951. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other RAPT Therapeutics news, insider William Ho sold 5,000 shares of RAPT Therapeutics stock in a transaction on Tuesday, January 24th. The shares were sold at an average price of $30.00, for a total value of $150,000.00. Following the transaction, the insider now directly owns 30,072 shares of the company’s stock, valued at $902,160. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Wendye Robbins purchased 2,500 shares of the business’s stock in a transaction on Tuesday, March 14th. The stock was purchased at an average cost of $18.99 per share, for a total transaction of $47,475.00. Following the completion of the acquisition, the director now directly owns 14,900 shares of the company’s stock, valued at approximately $282,951. The disclosure for this purchase can be found here. Insiders sold 20,742 shares of company stock valued at $532,352 over the last 90 days. Corporate insiders own 5.00% of the company’s stock.

Hedge Funds Weigh In On RAPT Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of RAPT. Swiss National Bank grew its holdings in RAPT Therapeutics by 7.6% in the first quarter. Swiss National Bank now owns 45,400 shares of the company’s stock worth $998,000 after purchasing an additional 3,200 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in RAPT Therapeutics by 23.7% in the first quarter. JPMorgan Chase & Co. now owns 13,575 shares of the company’s stock worth $299,000 after purchasing an additional 2,599 shares during the last quarter. MetLife Investment Management LLC grew its holdings in RAPT Therapeutics by 58.5% in the first quarter. MetLife Investment Management LLC now owns 11,028 shares of the company’s stock worth $243,000 after purchasing an additional 4,070 shares during the last quarter. Rhumbline Advisers grew its holdings in RAPT Therapeutics by 18.3% in the first quarter. Rhumbline Advisers now owns 21,961 shares of the company’s stock worth $483,000 after purchasing an additional 3,405 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in RAPT Therapeutics by 32.0% in the first quarter. Dimensional Fund Advisors LP now owns 285,325 shares of the company’s stock worth $6,274,000 after purchasing an additional 69,238 shares during the last quarter.

RAPT Therapeutics Company Profile

(Get Rating)

Rapt Therapeutics, Inc operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.